Cargando…

Impact of Cytological Sampling on EGFR Mutation Testing in Stage III-IV Lung Adenocarcinoma

Objectives. There have been advances in the identification and understanding of molecular subsets of lung cancer, defined by specific oncogenic aberrations. A number of actionable genetic alterations have been identified, such as the epidermal growth factor receptor (EGFR) mutation. We aimed to esta...

Descripción completa

Detalles Bibliográficos
Autores principales:	Davies, Rhian Siân, Smith, Christian, Edwards, Gwenllian, Butler, Rachel, Parry, Diane, Lester, Jason Francis
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2017
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5359447/ https://www.ncbi.nlm.nih.gov/pubmed/28367333 http://dx.doi.org/10.1155/2017/9614938

Ejemplares similares

Frequency and clinical features of BRAF mutations among patients with stage III/IV lung adenocarcinoma without EGFR/ALK aberrations
por: Kim, Ho Cheol, et al.
Publicado: (2019)

Impact of Radiotherapy Pattern on the Prognosis of Stage IV Lung Adenocarcinomas Harboring EGFR Mutations
por: Zhang, Yingyun, et al.
Publicado: (2021)

Independent prognostic value of fascin immunoreactivity in stage III–IV colonic adenocarcinoma
por: Puppa, G, et al.
Publicado: (2007)

Improved survival in patients with unresectable stage III EGFR ‐mutant adenocarcinoma with upfront EGFR‐tyrosine kinase inhibitors
por: Wang, Sheng‐Yuan, et al.
Publicado: (2021)

Radiation-induced sarcoma in a 10-year survivor with stage IV EGFR-mutated lung adenocarcinoma
por: Shibahara, Daisuke, et al.
Publicado: (2019)

Staging laparoscopy and peritoneal cytology in patients with early stage gastric adenocarcinoma
por: Allen, Casey J., et al.
Publicado: (2020)

Stage IV EGFR Mutation-Negative and ALK Mutation-Negative Lung Adenocarcinoma: Long-Term Survival is Possible
por: Kedia, Shiksha, et al.
Publicado: (2015)

Evaluation of liquid based cytology in detection of EGFR mutation in NSCLC by large samples
por: Dong, Zhengwei, et al.
Publicado: (2020)

Is MPP a good prognostic factor in stage III lung adenocarcinoma with EGFR exon 19 mutation?
por: Zhang, Tian, et al.
Publicado: (2017)

Thyroid transcription factor-1 as a prognostic indicator for stage IV lung adenocarcinoma with and without EGFR-sensitizing mutations
por: Park, Ji Young, et al.
Publicado: (2019)

Concurrent EGFR mutation and ALK rearrangement in stage IV lung adenocarcinoma—a case report and a literature review
por: Cipriano, Élia, et al.
Publicado: (2021)

The cost of unresectable stage III or stage IV melanoma in Italy
por: Maio, Michele, et al.
Publicado: (2012)

The Efficacy of Traditional Chinese Herbal Medicine in the Treatment of EGFR Mutated Stage IV Pulmonary Adenocarcinoma Patients Who Received First-Line EGFR-TKI Treatment
por: Hung, Hsiu-Ying, et al.
Publicado: (2016)

A real-world study comparing perioperative chemotherapy and EGFR-tyrosine kinase inhibitors for treatment of resected stage III EGFR-mutant adenocarcinoma
por: Chen, Chieh-Lung, et al.
Publicado: (2023)

Treatment decisions, clinical outcomes, and pharmacoeconomics in the treatment of patients with EGFR mutated stage III/IV NSCLC in Germany: an observational study
por: Schuette, Wolfgang, et al.
Publicado: (2018)

Real-world data analysis of immune checkpoint inhibitors in stage III-IV adenocarcinoma and squamous cell carcinoma
por: Sun, Meiling, et al.
Publicado: (2022)

Development and validation of nomogram models to predict radiotherapy or chemotherapy benefit in stage III/IV gastric adenocarcinoma with surgery
por: Ren, Xiangqing, et al.
Publicado: (2023)

The Association of EGFR Mutations with Stage at Diagnosis in Lung Adenocarcinomas
por: Cho, Jaeyoung, et al.
Publicado: (2016)

Efficacy of first-line tyrosine kinase inhibitor between unresectable stage III and stage IV EGFR-mutated non-small cell lung cancer patients
por: Liu, Yang, et al.
Publicado: (2023)

Radical Resection for Second EGFR-mutated Primary Lung Cancer Following Immune Checkpoint Inhibitor Monotherapy for Stage IV Lung Adenocarcinoma
por: Horibe, Ryota, et al.
Publicado: (2021)

Current treatment strategies for patients with only peritoneal cytology positive stage IV gastric cancer
por: Bausys, Augustinas, et al.
Publicado: (2021)

Direct sampling of metastatic ovarian carcinoma masquerading as endocervical adenocarcinoma in liquid-based cytology cervical sample
por: Gupta, Nalini, et al.
Publicado: (2014)

Detection of EGFR and KRAS gene mutations using suspension liquid-based cytology specimens in metastatic lung adenocarcinoma
por: Zhao, Huan, et al.
Publicado: (2017)

Japanese Lung Cancer Society Guidelines for Stage IV NSCLC With EGFR Mutations
por: Ninomiya, Kiichiro, et al.
Publicado: (2020)

Cytoplasmic ERβ1 expression is associated with survival of patients with Stage IV lung adenocarcinoma and an EGFR mutation at exon 21 L858R subsequent to treatment with EGFR-TKIs
por: He, Cheng, et al.
Publicado: (2019)

Detection of EGFR and KRAS Mutation by Pyrosequencing Analysis in Cytologic Samples of Non-Small Cell Lung Cancer
por: Lee, Seung Eun, et al.
Publicado: (2016)

Genomic and microenvironmental landscape of stage I follicular lymphoma, compared with stage III/IV
por: Los-de Vries, G. Tjitske, et al.
Publicado: (2022)

Short report: Performance evaluation of the Idylla™ KRAS and EGFR mutation tests on paraffin-embedded cytological NSCLC samples
por: Offerman, Saskia, et al.
Publicado: (2021)

Predicting Tyrosine Kinase Inhibitor Treatment Response in Stage IV Lung Adenocarcinoma Patients With EGFR Mutation Using Model-Based Deep Transfer Learning
por: Hou, Runping, et al.
Publicado: (2021)

Benefit from Adjuvant TKIs Versus TKIs Plus Chemotherapy in EGFR-Mutant Stage III-pN2 Lung Adenocarcinoma
por: Li, Qiwen, et al.
Publicado: (2021)

A Robust Seven-Gene Signature Associated With Tumor Microenvironment to Predict Survival Outcomes of Patients With Stage III–IV Lung Adenocarcinoma
por: Zhao, Hao, et al.
Publicado: (2021)

Results of systemic treatment of cutaneous melanoma in inoperable stage III and IV
por: Cybulska-Stopa, Bożena, et al.
Publicado: (2013)

Phase III study of gefitinib or pemetrexed with carboplatin in EGFR-mutated advanced lung adenocarcinoma
por: Patil, Vijay Maruti, et al.
Publicado: (2017)

Stage IV jejunal adenocarcinoma: a multimodal therapeutic success story
por: Seomangal, Karishma, et al.
Publicado: (2019)

Dysgonomonas capnocytophagoides Bacteremia in a Patient With Stage IV Colon Adenocarcinoma
por: Schall, Sarah E, et al.
Publicado: (2021)

Developing Preoperative Nomograms to Predict Any-Stage and Stage III-IV Endometriosis in Infertile Women
por: Guo, Zaixin, et al.
Publicado: (2020)

EGFR mutation testing in lung cancer: a review of available methods and their use for analysis of tumour tissue and cytology samples
por: Ellison, Gillian, et al.
Publicado: (2013)

Staging CT and Diagnostic Laparoscopy With Cytology Prior to the Treatment of Pancreatic Adenocarcinoma: A Case Series
por: Panse, Neal S, et al.
Publicado: (2022)

Aspiration Biopsy Cytology. Part 2. Cytology of Infradiaphragmatic Organs. Monographs in Cytology. Vol. 7
por: Butler, E. B.
Publicado: (1980)

Radiochemotherapy in stage III/IV nonmetastatic squamous cell head and neck cancer
por: Schäfer, C, et al.
Publicado: (2006)

Cannot write session to /tmp/vufind_sessions/sess_nqcr0ohta6jhn6khj6v8pda7bg